Skip to main content

Hormone-free solution for vaginal atrophy

Objective

Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts on the quality of life, relationships, everyday activities and confidence of women sufferers. It is associated with thinning, drying and inflammation of the vaginal tissue. It is experienced by 80% of all women globally and is the most common symptom of the menopause. Over 70% of Breast Cancer Survivors will also suffer from VA due to side effects of chemotherapy and the cancer-blocker drugs they take further exacerbate symptoms of VA. Current treatment options for VA, primarily pharmaceuticals are either ineffective or poorly tolerated. In the EU and US, 3.6m patients of VA reject existing treatments.
AVeta- a medical device delivering the only hormone free, affordable and safe targeted therapy for all women suffering from VA. Solution is based on pathophysiology of wound healing and will be prescribed by a Clinician in an outpatient setting and women will self-administer the therapy monthly at home.

Coordinator

AVETA MEDICAL LIMITED
Net EU contribution
€ 2 500 000,00
Address
34 New Road
H91 T6TC Galway
Ireland

See on map

Region
Ireland Northern and Western West
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 1 314 567,50